Last $5.57 USD
Change Today -0.16 / -2.79%
Volume 278.0K
GALT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics inc (GALT) Snapshot

Open
$5.77
Previous Close
$5.73
Day High
$5.82
Day Low
$5.50
52 Week High
02/26/14 - $19.11
52 Week Low
08/13/14 - $4.28
Market Cap
122.8M
Average Volume 10 Days
365.5K
EPS TTM
$-0.83
Shares Outstanding
22.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALECTIN THERAPEUTICS INC (GALT)

Related News

No related news articles were found.

galectin therapeutics inc (GALT) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics inc (GALT) Details

Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

6 Employees
Last Reported Date: 03/21/14
Founded in 2000

galectin therapeutics inc (GALT) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $569.7K
Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $127.3K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $260.0K
Compensation as of Fiscal Year 2013.

galectin therapeutics inc (GALT) Key Developments

Pomerantz LLP Announces the Filing of Class Action Against Galectin Therapeutics, Inc. and Certain Officers

Pomerantz LLP has filed a class action lawsuit against Galectin Therapeutics, Inc. and certain of its officers. The class action, filed in United States District Court, District of Nevada, and docketed under 14-cv-01287, is on behalf of a class consisting of all persons or entities who purchased Galectin securities between January 6, 2014 and July 28, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the Exchange Act). The complaint alleges that throughout the class period, defendants made false and/or misleading statements, and failed to disclose material adverse facts about the company's business, operations, prospects and performance. Specifically, during the class period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the company was utilizing the services of paid stock promoters to disseminate positive but misleading reports about Galectin's prospects; (2) moreover, GR-MD-02 did not provide the benefits suggested by Defendants when discussing the patent the company was awarded or the Phase 1 clinical trial it was conducting; and (3) as a result of the above, the company's financial statements were materially false and misleading at all relevant times.

Galectin Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 01:00 PM

Galectin Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 01:00 PM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Peter G. Traber, Chief Executive Officer, President, Chief Medical Officer and Director.

Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Galectin Therapeutics, Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total operating loss was $3.375 million compared with $2.547 million for the same period last year. Net loss applicable to common stock was $3.731 million or $0.17 basic and diluted per share compared with $11.641 million or $0.72 basic and diluted per share for the same period last year. Excluding non-cash charge, the increase in net loss applicable to common stock in the quarter ended June 30, 2014 over 2013 is primarily due to increases in clinical trial costs related to Phase 1 clinical trial, non-cash stock-based compensation expense and legal costs. For the six months, the company reported total operating loss was $8.219 million compared with $5.755 million for the same period last year. Net loss applicable to common stock was $9.139 million or $0.42 basic and diluted per share compared with $15.113 million or $0.94 basic and diluted per share for the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $5.57 USD -0.16

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit www.galectintherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.